|Free Dividend Report|
|Stock Splits Calendar|
|ADMS Stock Split History|
|Preferred Stock Newsletter|
|ADMS Options Chain|
|Stock Message Boards|
Adamas Pharmaceuticals (ADMS) has 2 splits in our ADMS split history database. The first split for ADMS took place on February 16, 1999. This was a 3 for 2 split, meaning for each 2 shares of ADMS owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. ADMS's second split took place on January 18, 2000. This was a 3 for 2 split, meaning for each 2 shares of ADMS owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.
When a company such as Adamas Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the ADMS split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adamas Pharmaceuticals shares, starting with a $10,000 purchase of ADMS, presented on a split-history-adjusted basis factoring in the complete ADMS split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-16.13%|
|About Adamas Pharmaceuticals|
|Adamas Pharmaceuticals focuses on therapies to reduce the burden of neurological diseases on patients, caregivers, and society. Co.'s product, GOCOVRI (amantadine) extended-release capsules, is for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Co.'s partnered product, Namzaric® (memantine hydrochloride extended release and donepezil hydrochloride) capsules, are for the treatment of moderate to severe dementia of an Alzheimer's type, marketed in the U.S. by Allergan plc under a license agreement between Co. and Forest Laboratories Holdings Limited, a subsidiary of Allergan plc. According to our ADMS split history records, Adamas Pharmaceuticals has had 2 splits.|
|ADMS Split History Table|
|02/16/1999||3 for 2|
|01/18/2000||3 for 2|
|Healthcare Stock Splits|
|ADMS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: ADMS shares outstanding history